Takahiro Uchida

Takahiro Uchida

Auto-generated profile, based on publicly available information

Takahiro Uchida

Department of Respiratory Medicine and Allergy Center, Saitama Medical University, Saitama, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Asia Pacific Allergy
Verified
Journal Article
Open access
PDF file
TUTakahiro Uchida
Takahiro Uchida
KNKazuyuki Nakagome
Kazuyuki Nakagome
HIHidetoshi Iemura
Hidetoshi Iemura
ENErika Naito
Erika Naito
SMSachiko Miyauchi
Sachiko Miyauchi
MNMakoto Nagata
Makoto Nagata
Background: Allergen immunotherapy (AIT) is a specific treatment of administering clinically important allergens to patients who have allergic diseases. In Japan, the standardized house dust mite (HDM) allergen for subcutaneous immunotherapy (SCIT) was approved in 2015, and we then introduced rush-immunotherapy (rush-IT) using the standardized HDM allergen for HDM-sensitive asthmatics. However, little data are available on the safety and effectiveness of rush-HDM-IT, especially for Japanese asthmatics. Objective: The objective of this study was to examine the safety and clinical effectiveness of rush-IT using the standardized HDM for HDM-sensitive Japanese asthmatics. Methods: Thirteen HDM-sensitive asthmatics who received rush-HDM-IT and 12 HDM-sensitive asthmatic controls were enrolled. To evaluate the safety, the number of systemic reaction (SR) events, including anaphylaxis, was assessed. To evaluate the effectiveness, changes in the treatment step, dose of inhaled corticosteroid, and asthma control after rush-HDM-IT and the subsequent maintenance SCIT were assessed. Changes in the HDM-induced production of type 2 cytokines from peripheral blood mononuclear cells were also evaluated. Results: Among the 12 patients who received rush-IT, 4 (30.7%) experienced a SR and 3 (23.1%) experienced anaphylaxis. However, the anaphylaxis was not severe (grade 3) in all cases, and they recovered in a short time. The treatment step of asthma was better and the dose of inhaled corticosteroid was lower in the rush-HDM-IT group than in the control group. The HDM-induced production of both interleukin (IL)-5 and IL-13 from peripheral blood mononuclear cells was significantly lower in the rush-HDM-IT group than in the control group. Conclusion: Rush-HDM-IT can be performed relatively safely in Japanese asthmatics. Furthermore, rush-HDM-IT and the subsequent maintenance SCIT provided clinical improvement in asthma patients, and was accompanied by the suppression of HDM-specific Th2-mediated systemic immune responses.

7 October 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
TUTakahiro Uchida
Takahiro Uchida
KNKazuyuki Nakagome
Kazuyuki Nakagome
KHKosuke Hashimoto
Kosuke Hashimoto
HIHidetoshi Iemura
Hidetoshi Iemura
YSYuki Shiko
Yuki Shiko
HKHiroshi Kagamu
Hiroshi Kagamu
Background: The relationship between eosinophilia and cancer development has recently been investigated. However, the role of eosinophils in tumor immunity, particularly in the context of immune checkpoint inhibitor (ICI) therapy, remains poorly understood.Methods: We investigated the relationship between peripheral blood eosinophil and T-lymphocyte subsets and the clinical characteristics of patients undergoing anti-programmed cell death-1 (PD-1) monotherapy for non-small cell lung cancer (NSCLC). The study included 204 patients treated with nivolumab monotherapy, and clinical data and treatment responses were recorded. PBMCs were collected from 44 out of 204 patients before treatment to analyze T-lymphocyte subsets, focusing on their correlation with blood eosinophils.Results: The percentage of blood eosinophils before nivolumab treatment was positively correlated with the percentage of effector memory subsets in both CD4+ (r = 0.43, p = 0.0045) and CD8+ T cells (r = 0.35, p = 0.020). It was negatively correlated with the percentage of naïve subsets of CD4+ T cells and positively correlated with the percentage of inducible T cell co-stimulator cells among CD8+ T cells. Patients with higher eosinophil levels (≥1.7%) before nivolumab treatment exhibited significantly longer progression-free survival (log-rank p = 0.014) and overall survival (log-rank p = 0.001) than those with lower eosinophil levels. An early increase in the eosinophil count after treatment was also associated with a better response to nivolumab.Conclusion: Higher blood eosinophil levels may indicate activated T-cell immunity and may be a promising biomarker for the efficacy of anti-PD-1 monotherapy in patients with NSCLC.

15 November 2021 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TUTakahiro Uchida
Takahiro Uchida
YUYoshitaka Uchida
Yoshitaka Uchida
MTMasao Takahashi
Masao Takahashi
KMKenji Masaki
Kenji Masaki
HSHideaki Sato
Hideaki Sato
MNMakoto Nagata
Makoto Nagata
Yellow nail syndrome (YNS) is a rare disease comprising the clinical triad of yellow nail discoloration, pleural effusion, and lower limb lymphedema. We encountered a difficult-to-treat case of YNS in which the diagnosis was finally made based on intranodal lymphangiography. An 84-year-old man was admitted to our hospital with pleural effusion and yellow-green discoloration of the nails, accompanied by onychomycosis and limb lymphedema. Intranodal lymphangiography revealed a slow contrast flow and narrowing of the thoracic duct, suggesting lymphatic duct dysplasia and leading to the diagnosis of YNS.

25 April 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
HKHirofumi Kamata
Hirofumi Kamata
KTKazufumi Takamatsu
Kazufumi Takamatsu
KFKoichi Fukunaga
Koichi Fukunaga
SCShotaro Chubachi
Shotaro Chubachi
KNKensuke Nakagawara
Kensuke Nakagawara
AYAkihito Yokoyama
Akihito Yokoyama

21 March 2023 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
TUTakahiro Uchida
Takahiro Uchida
KIKeisuke Ishizawa
Keisuke Ishizawa
SYSanehiro Yogi
Sanehiro Yogi
KKKazuki Katayama
Kazuki Katayama
RSRyu Sekiya
Ryu Sekiya
MNMakoto Nagata
Makoto Nagata
Anorexia nervosa causes various complications accompanying weight loss and malnutrition. Al-though bilateral spontaneous pneumothorax (SBSP) is uncommon, caution is needed in anorexia nervosa because this complication can be fatal. We encountered a 17-year-old girl with SBSP from emphysematous pulmonary changes due to anorexia nervosa. She was hospitalized with SBSP during treatment for anorexia nervosa. Chest tube drainage was started on admission, but no improvement was achieved. Surgery was therefore performed. Lung lesions on surgical speci-mens demonstrated malnutrition-induced emphysematous changes, a risk factor for SBSP. Atten-tion should be paid to the occurrence of SBSP during the clinical course of anorexia nervosa.

28 February 2022 in COVID
Verified
Journal Article
Open access
PDF file
KYKazuhiro Yokota
Kazuhiro Yokota
HNHisashi Noma
Hisashi Noma
NTNorihito Tarumoto
Norihito Tarumoto
NINoriomi Ishibashi
Noriomi Ishibashi
SSSakai Sakai
Sakai Sakai
TMToshihide Mimura
Toshihide Mimura
Coronavirus disease 2019 (COVID-19) is associated with fatal acute respiratory distress syndrome, which can be ameliorated by methylprednisolone pulse therapy, thereby reducing the risk of progression to respiratory failure and death. We aimed to determine the efficacy and safety of methylprednisolone pulse therapy for patients with COVID-19 pneumonia. In this retrospective, observational cohort study, seventy patients (age, 35–91 years) who were admitted to Saitama Medical University Hospital in Japan between March 2020 and January 2021 due to COVID-19 pneumonia were included. The difference in mortality between the methylprednisolone pulse therapy (n = 22) and dexamethasone therapy (n = 48) groups was the primary outcome. Between-group differences in the average length of intensive care unit stay, duration of invasive mechanical ventilation, and incidence of treatment-related adverse events were the secondary outcomes. The methylprednisolone pulse therapy group showed a significantly lower mortality rate (3.8% vs. 20.2%, p = 0.006) and increased survival rate compared with the dexamethasone therapy group (p = 0.044). Additionally, without statistical significance, the average length of intensive care unit stay tended to be shorter in the methylprednisolone pulse therapy group (11.5 ± 6.1 days) than in the dexamethasone therapy group (22.3 ± 23.1 days) (p = 0.793). The average duration of invasive mechanical ventilation also tended to be shorter in the methylprednisolone pulse therapy group (15.3 ± 10.1 vs. 28.8 ± 9.2 days, p = 0.120). There were no significant differences in the incidence of treatment-related serious adverse events between the two groups. In conclusion, methylprednisolone pulse therapy for patients with COVID-19 pneumonia significantly reduced mortality and increased the survival rate compared to conventional dexamethasone therapy.